Vanadium compounds affect growth and morphology of human rhabdomyosarcoma cell line

Wojciech Dąbroś1, Anna Adamczyk, Katarzyna Ciurkot

  • 1Chair of Pathomorphology, Faculty of Medicine, Collegium Medicum Jagiellonian University, Cracow, Poland. mpdabros@cyf-kr.edu.pl

Insights

Vanadium compounds inhibit rhabdomyosarcoma (RMS) cell growth. Concentrations above 40 μM caused cell death, with RMS cells showing resistance to orthovanadate.

Area of Science:

  • Inorganic Chemistry
  • Cell Biology
  • Oncology

Background:

  • Rhabdomyosarcoma (RMS) is a pediatric cancer.
  • Vanadium compounds have shown cytotoxic effects on cancer cells.
  • Understanding the impact of vanadium on RMS is crucial for potential therapeutic strategies.

Purpose of the Study:

  • To investigate the effect of four vanadium compounds on the growth of rhabdomyosarcoma (RMS) cells.
  • To determine the sensitivity and resistance of RMS cells to different vanadium salts.
  • To compare the sensitivity of RMS cells to other human cancer cell lines.

Main Methods:

  • Incubation of RMS cells with four vanadium compounds: BMOV, vanadyl sulphate, ortho-vanadate, and meta-vanadate.
  • Quantification of cell growth inhibition using crystal violet (CV) and MTT assays.
  • Statistical analysis of results compared to control groups.
  • Electron microscopy for cellular morphology assessment.

Main Results:

  • Statistically significant growth inhibition of RMS cells was observed after 48 h incubation with vanadium compounds (10-40 μM).
  • Vanadium concentrations higher than 40 μM led to complete cell destruction.
  • RMS cells exhibited resistance to orthovanadate (approx. 40 μM), showing higher resistance compared to other tested human cancer cell lines.

Conclusions:

  • Vanadium compounds effectively inhibit RMS cell growth in vitro.
  • RMS cells display a degree of resistance to orthovanadate, suggesting differential sensitivity among cancer types.
  • Further research into vanadium-based therapies for RMS is warranted, considering dose-dependent cytotoxic effects and cell-specific resistance.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...